Calidi Biotherapeutics Inc., a clinical-stage immuno-oncology company headquartered in San Diego, United States, continues to make strides in the health care sector with its innovative approach to cancer treatment. Specializing in the development of next-generation targeted immunotherapies, Calidi Biotherapeutics focuses on creating treatments that not only attack solid tumors but also empower the immune system to identify and eradicate cancer cells throughout the body. This pioneering approach positions the company at the forefront of immuno-oncology, offering its services on a global scale.
Despite its promising technological advancements, Calidi Biotherapeutics has experienced limited media coverage recently. The most recent headline, dated December 5, 2025, highlighted an upcoming interview on RedChip, indicating a potential increase in visibility and investor interest. As of December 18, 2025, the company’s stock closed at $1.36. Over the past year, the share price has seen significant volatility, ranging from a low of $1.10 on November 6, 2025, to a high of $19.20 on July 8, 2025. This fluctuation underscores the speculative nature of biotechnology investments, particularly for companies in the clinical stage of development.
Financially, Calidi Biotherapeutics presents a mixed picture. The company’s negative price-to-earnings ratio of -0.16 reflects its current lack of profitability, a common scenario for firms heavily invested in research and development. However, the price-to-book ratio of 1.54 suggests that the market values the company at approximately 1.5 times its book value, indicating investor confidence in its long-term potential. With a market capitalization of $9,950,000, Calidi Biotherapeutics remains a relatively small player in the biotechnology sector, yet its innovative focus on immuno-oncology could drive future growth.
As Calidi Biotherapeutics continues to advance its clinical programs, the company is poised to capitalize on the growing demand for effective cancer therapies. Its commitment to developing groundbreaking immunotherapies positions it as a key player in the evolving landscape of cancer treatment. Investors and industry observers will closely monitor the company’s progress, particularly as it seeks to translate its scientific advancements into commercial success.
